Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Cytomegalovirus Retinitis (CMV Retinitis) intravenously, injected directly into the eye or through an intravitreal implant. CMV retinitis, is the most common severe infection affecting the eye in patients with AIDS. The disease typically occurs during the late stages of AIDS when individuals have a T cell , or CD4 count, of less than 100. Left untreated, CMV can take a person's sight within two to six months. Treatment continued: The vitrasert implant procedure has recently been shown to be superior to intravenous therapy in controlling the CMV infection, as reported by Dr. David Musch from the University of Michigan Kellogg Eye Center in the New England Journal of Medicine. The most common symptoms of Cytomegalovirus retinitis are: Floaters Light flashes Blind spots Blurred vision Obstructed areas of vision Sudden decrease of vision CMV Retinitis is a adventitious condition caused by Cytomegalovirus. While CMV is found in almost everyone, and is usually fought off by the immune system, for people who are immunocompromised, by diseases, transplants, or chemotherapy the virus is not adequately destroyed and can cause damage to the eye and the rest of the body. HIV positive persons are most at risk, especially when the CD4 cell count decreases. CMV is a common virus that infects those who are HIV positive. Treatment: The most common prescribed medications for cytomegalovirus retinis are: ganciclovir (Cytovene), foscarnet (Foscavir) and cidofovir (Vistide). These drugs can be administered orally, The vitrasert implant is surgically placed in the eye and so delivers a high concentration of drug directly to where the infection is located. Retinal surgeons at the Kellogg Eye Center perform these surgeries on a routine basis. The implant procedure is done as an outpatient and is effective for approximately six to nine months, at which time a second device can be implanted. Images: Sources: 1. http://www.redatlas.org/fr_ind ex.htm?/RAPages/G/G000.htm 2. http://www.mamashealth.com/ eye/cmvret.asp 3. http://en.wikipedia.org/wiki/Cy tomegalovirus_retinitis 4. http://www.kellogg.umich.edu/p atientcare/conditions/cmv.html 5. http://www.uveitissociety.org/pa ges/diseases/cmvr.html developed by: Darren Stilwell